» Articles » PMID: 19628188

The Relative Renal Safety of Iodixanol Compared with Low-osmolar Contrast Media: a Meta-analysis of Randomized Controlled Trials

Overview
Publisher Elsevier
Date 2009 Jul 25
PMID 19628188
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: We sought to compare the nephrotoxicity of the iso-osmolar contrast medium, iodixanol, to low-osmolar contrast media (LOCM).

Background: Contrast-induced acute kidney injury (CI-AKI) is a common cause of in-hospital renal failure. A prior meta-analysis suggested that iodixanol (Visipaque, GE Healthcare, Princeton, New Jersey) was associated with less CI-AKI than LOCM, but this study was limited by ascertainment bias and did not include the most recent randomized controlled trials.

Methods: We searched Medline, Embase, ISI Web of Knowledge, Google Scholar, Current Contents, and International Pharmaceutical Abstracts databases, and the Cochrane Central Register of Controlled Trials from 1980 to November 30, 2008, for randomized controlled trials that compared the incidence of CI-AKI with either iodixanol or LOCM. Random-effects models were used to calculate summary risk ratios (RR) for CI-AKI, need for hemodialysis, and death.

Results: A total of 16 trials including 2,763 subjects were pooled. There was no significant difference in the incidence of CI-AKI in the iodixanol group than in the LOCM group overall (summary RR: 0.79, 95% confidence interval [CI]: 0.56 to 1.12, p = 0.19). There was no significant difference in the rates of post-procedure hemodialysis or death. There was a reduction in CI-AKI when iodixanol was compared with ioxaglate (RR: 0.58, 95% CI: 0.37 to 0.92; p = 0.022) and iohexol (RR: 0.19, 95% CI: 0.07 to 0.56; p = 0.002), but no difference when compared with iopamidol (RR: 1.20, 95% CI: 0.66 to 2.18; p = 0.55), iopromide (RR: 0.93, 95% CI: 0.47 to 1.85; p = 0.84), or ioversol (RR: 0.92, 95% CI: 0.60 to 1.39; p = 0.68).

Conclusions: This meta-analysis including 2,763 subjects suggests that iodixanol, when compared with LOCM overall, is not associated with less CI-AKI. The relative renal safety of LOCM compared with iodixanol may vary based on the specific type of LOCM.

Citing Articles

Dynamic coronary roadmap in percutaneous coronary intervention: a systematic review and meta-analysis.

Behnoush A, Ramandi A, Mahajan S, Altibi A, Samavarchitehrani A, Gupta R BMC Cardiovasc Disord. 2024; 24(1):681.

PMID: 39592941 PMC: 11590536. DOI: 10.1186/s12872-024-04350-8.


Management of Patients With Kidney Disease in Need of Cardiovascular Catheterization: A Scientific Workshop Cosponsored by the National Kidney Foundation and the Society for Cardiovascular Angiography and Interventions.

Prasad A, Palevsky P, Bansal S, Chertow G, Kaufman J, Kashani K J Soc Cardiovasc Angiogr Interv. 2024; 1(6):100445.

PMID: 39132354 PMC: 11307971. DOI: 10.1016/j.jscai.2022.100445.


Diluted contrast media combined with high-resolution C-arm CT for evaluating apposition of flow diversions in a porcine model.

Long S, Yu S, Shi C, Ma J, Li Z, Cheng J Interv Neuroradiol. 2024; :15910199241261763.

PMID: 38881346 PMC: 11571160. DOI: 10.1177/15910199241261763.


Acute Kidney Injury After Percutaneous Coronary Intervention Guided by Intravascular Ultrasound.

Tran Duc M, Nguyen Quoc T, Nguyen B, Vu Quang N, Nguyen Duc N, Nguyen Duc H Cureus. 2024; 16(3):e57164.

PMID: 38681391 PMC: 11056017. DOI: 10.7759/cureus.57164.


The use of intravascular contrast media in patients with impaired kidney function - joint clinical practice position statement of the Polish Society of Nephrology and the Polish Medical Society of Radiology.

Chmielewski M, Serafin Z, Kaminska D, Skrobisz K, Kozak O, Olczyk P Pol J Radiol. 2024; 89:e161-e171.

PMID: 38550960 PMC: 10976626. DOI: 10.5114/pjr.2024.136950.